期刊文献+

Fas系统与肿瘤免疫的关系 被引量:1

The Relationship Between Fas System and Tumor Immunity
下载PDF
导出
摘要 Fasl是TNF家族成员 ,通过与靶细胞表面的死亡受体Fas蛋白结合 ,诱导靶细胞发生凋亡。许多研究表明Fas系统在肿瘤发生、发展和肿瘤免疫逃逸等方面发挥着重要的作用。 Fas ligand (Fasl) is a member of the tumor necrosis factor (TNF) family.Fasl has been shown to trigger apoptosis in Fas expressing cells by binding its receptor Fas.The Fas/Fasl system is play an important role in the occurrence?progression and escapte from the host immune system of the tumor This paper reviews the relationship between Fas system and tumor immunity.
出处 《肿瘤防治杂志》 2002年第4期478-480,共3页 China Journal of Cancer Prevention and Treatment
关键词 FAS FASL 肿瘤 免疫学 肿瘤逃逸 综述文献 fas/fasl tumor immunity tumor escape review literature
  • 相关文献

参考文献19

  • 1[1]Natoli G, lanni A, Costanzo A, et al. Resistance to Fas-mediatedapoptosis in human hepatoma cells [J]. Oncogene, 1995, 11 (6):1157 - 1164. 被引量:1
  • 2[2]Kayagaki N, Kawasaki A, Abata A, et al. Metalloprotenase-medicatedrelease of human Fas ligand [J] .J Exp Med, 1995,182(6): 1777 -1783. 被引量:1
  • 3[3]Griffith TS, Brunner T, Fletcher S. M,et al. Fas ligand-induced apoptosis as mechanism of Immune privilege [ J ]. Science, 1995, 270(5239): 1189 - 1192. 被引量:1
  • 4[4]Bellgrau D,Gold D,Selawry H,et al.A role for CD 95 ligand in preventing graft rejection[J ]. Nature, 1995,377(6550) :630 - 632. 被引量:1
  • 5[5]Halapi E.Oligoclonal T cells in human cancer[J].Med oncol, 1998,15(4) :203 - 211. 被引量:1
  • 6[6]Kelly MD, King J, Cherian M, et al. Randomited trial of preoperativecimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes [ J ]. cancer, 1999,84 (7):1658- 1663. 被引量:1
  • 7[7]O'Connell, Benner MW, Collins JK,et al. The Fas counterattack cancer as asite of immune privilege[J]. Immunol Today, 1999,20( 1 ):46- 52. 被引量:1
  • 8[8]Von Reyher U,Strater J,Kittstein W,et al. Colon carcinoma cells usedifferent mechanisms to escape CD 95-mediated apoptosis[J]. CancerRes, 1998,58(2) :526 - 534. 被引量:1
  • 9[9]NambuY,HughesSJ,HamstraD,etal. LackofcellsurfaceFas/Apo1 expression in pulmonary adenocascinomas [J] .J Clin Investt, 1998,101(5):1102- 1110. 被引量:1
  • 10[10]Reimer T,Hermring C,Koczan D,et al. Fasl:Fas ration-a prognosticfactor in breast carcinomas[J] .Cancer Res,2000,60(4):822- 828. 被引量:1

同被引文献3

  • 1Nagao M, Nakajima Y ,Hisanaga M, et al. The alterarion of Fas receptor and ligand system in hepatocellular carcinomas:how do hepatoma cells escape from the host immue surveillance in vivo?[J]. Hepatology, 1999,30(2):413-421. 被引量:1
  • 2Jodo S, Kobayashi S, Nakajima Y, et al. Elevated serum levels of soluble Fas/APO-1(CD95) in patients with hepatocellular carcinoma[J]. Clin Exp Immunol, 1998,112(1):166-171. 被引量:1
  • 3张俊峰,孙宝友,石学涛,衣龙海,李胜.原发性肝癌中Fas表达及其与细胞凋亡的关系[J].中国癌症杂志,2003,13(2):147-149. 被引量:1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部